Merit Medical Systems, Inc. $MMSI Shares Sold by Royal Bank of Canada

Royal Bank of Canada lessened its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 4.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 921,330 shares of the medical instruments supplier’s stock after selling 45,005 shares during the quarter. Royal Bank of Canada’s holdings in Merit Medical Systems were worth $63,507,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in MMSI. State Street Corp grew its position in Merit Medical Systems by 1.5% in the fourth quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock worth $196,645,000 after acquiring an additional 32,459 shares during the period. Conestoga Capital Advisors LLC raised its position in Merit Medical Systems by 3.9% in the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock valued at $149,407,000 after purchasing an additional 81,030 shares during the period. Fuller & Thaler Asset Management Inc. raised its position in Merit Medical Systems by 12.7% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after purchasing an additional 234,682 shares during the period. Wellington Management Group LLP lifted its stake in shares of Merit Medical Systems by 7.0% in the 4th quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock valued at $116,963,000 after purchasing an additional 86,504 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Merit Medical Systems by 1.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock valued at $85,287,000 after purchasing an additional 12,285 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Stock Performance

Shares of MMSI opened at $85.01 on Friday. The stock has a 50-day simple moving average of $69.87 and a 200-day simple moving average of $71.78. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.46 and a current ratio of 5.08. The stock has a market capitalization of $5.07 billion, a PE ratio of 35.13, a PEG ratio of 2.64 and a beta of 0.52. Merit Medical Systems, Inc. has a 1 year low of $59.74 and a 1 year high of $94.75.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. The company had revenue of $418.84 million for the quarter, compared to the consensus estimate of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.97%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, analysts predict that Merit Medical Systems, Inc. will post 3.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on MMSI shares. Piper Sandler upped their target price on shares of Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a research report on Friday. Robert W. Baird set a $98.00 price target on shares of Merit Medical Systems in a research report on Friday. Citigroup reissued an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Weiss Ratings lowered shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Finally, Barrington Research set a $114.00 price objective on shares of Merit Medical Systems in a research report on Friday. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and a consensus target price of $100.30.

Insider Buying and Selling at Merit Medical Systems

In other Merit Medical Systems news, insider Brian G. Lloyd purchased 2,000 shares of Merit Medical Systems stock in a transaction that occurred on Thursday, May 7th. The stock was purchased at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the transaction, the insider directly owned 2,000 shares in the company, valued at $125,240. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.70% of the stock is owned by company insiders.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q2 results exceeded expectations: Merit reported revenue of $418.8 million, up 9.5% year over year and above the $405.3 million consensus estimate. Non-GAAP EPS rose 18% to $1.19, beating estimates of $0.96; GAAP operating margin also improved to 14.4% from 12.3%. Merit Medical Reports Second Quarter 2026 Results and Updates Full-Year 2026 Guidance
• Positive Sentiment: 2026 guidance was raised: Management now expects full-year adjusted EPS of $4.25-$4.35, above the $3.98 analyst consensus. Broad-based product growth, revenue gains and expanding margins supported the improved outlook. MMSI Q2 Earnings, Revenues Beat Estimates; 2026 Guidance Raised
• Positive Sentiment: Analyst targets moved higher: Needham raised its target to $101 and maintained a Buy rating; BTIG lifted its target to $105 and maintained Buy; and JPMorgan raised its target to $95 with an Overweight rating. These revisions indicate increased confidence in Merit’s growth and earnings trajectory. Analysts Increase Forecasts After Strong Q2 Results
• Neutral Sentiment: Analyst opinion remains mixed: Wells Fargo raised its target to $83 but retained an Equal Weight rating, leaving its target below the stock’s recent trading level. Wells Fargo Raises Merit Medical Price Target
• Negative Sentiment: Cash generation weakened: Year-to-date operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million, a potential concern despite the strong earnings performance. Merit Medical Second Quarter Results

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.